651734-57-5

Basic information

• Product Name: Carbamic acid, (2,6-difluoro-3,5-dimethoxyphenyl)-, 1,1-dimethylethyl ester
• CAS NO: 651734-57-5
• Molecular Formula: C13H17F2NO4
• Molecular Weight: 289.279
• Mol File: 651734-57-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Carbamic acid, (2,6-difluoro-3,5-dimethoxyphenyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (2,6-difluoro-3,5-dimethoxyphenyl)-, 1,1-dimethylethyl ester(651734-57-5)
• EPA Substance Registry System: Carbamic acid, (2,6-difluoro-3,5-dimethoxyphenyl)-, 1,1-dimethylethyl ester(651734-57-5)

Safety Data

• Hazardous Substances Data: 651734-57-5(Hazardous Substances Data)

Upstream product

• 651734-55-3 methyl 2,6-difluoro-3,5-dimethoxybenzoate 
• 2150-37-0 methyl 3,5-dimethoxybenzoate 
• 651734-56-4 2,6-difluoro-3,5-dimethoxybenzoic acid 
• 75-65-0 tert-butyl alcohol 
• 26386-88-9 diphenyl phosphoryl azide 

Downstream Products

• 651734-54-2 2,6-difluoro-3,5-dimethoxybenzeneamine 

Relevant articles and documents

HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR

This disclosure relates to heterocyclics as selective inhibitors of the fibroblast growth factor receptor 4 (FGFR-4), in particular relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.

Kinase inhibitors

This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimido-pyrimidines, pyridopyrimidines, naphthyridines, and pyridopyrazines of the general formula: that inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediate compounds for their synthesis, as well as pharmaceutical compositions and methods for their use in treating, inhibiting or preventing maladies associated with cell proliferative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer.